Cariprazine is a dopamine D3-preferring 
INTRODUCTION
Although there are several agents that have received regulatory approval for the treatment of bipolar disorder, it is often difficult to select the treatment(s) that will result in sufficient reduction in symptoms together with reasonable tolerability and safety.
Moreover, although most available treatments are approved for the treatment of acute mania, fewer are approved for both manic and mixed episodes, fewer still for maintenance treatment, and only two for the treatment of acute bipolar depression [1, 2] .
The agents themselves vary greatly in terms of ease of use and tolerability [1, 2] . [22] , and a systematic review with emphasis on the chemistry, pharmacodynamics, and pharmacokinetics of cariprazine [23] .
PHARMACODYNAMICS AND PHARMACOKINETICS
The pharmacodynamics and pharmacokinetics of cariprazine are reviewed in more detail elsewhere [22, 23] . Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist [24] .
The in vitro binding profile of cariprazine is summarized in Table 1 . Table 1 In vitro binding a nities for cariprazine in human receptors [24] Although the pharmacokinetics of cariprazine in subjects with bipolar disorder is not known, the pharmacokinetics of cariprazine was tested in small short-term studies in both healthy volunteers and in subjects with schizophrenia, with similar results [25] .
Maximum concentration was observed in 3−4 h under fasting conditions, with food causing a slight delay but no significant effect on the extent of absorption. The mean half-life for cariprazine was 2-5 days over a dose range of 1.5-12.5 mg in the subjects with schizophrenia.
Cariprazine is metabolized by cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, by cytochrome P450 2D6 (CYP2D6) [26] .
There are two active metabolites of note, desmethyl-cariprazine and didesmethylcariprazine. Didesmethyl-cariprazine's half-life is substantially longer than that for cariprazine and systemic exposure to didesmethyl-cariprazine can be several times higher than that for cariprazine. In the studies for bipolar mania/mixed episodes, subjects could receive up to 3 weeks of randomized treatment. The primary efficacy NA not applicable, ND not disclosed measure was the Young Mania Rating Scale (YMRS) total score; the primary outcome was change from baseline on the YMRS total score at the 3-week endpoint. Figure 1 [27] [28] [29] provides an overview of the YMRS total score difference from placebo at endpoint for the three studies. 
SHORT-TERM CLINICAL TRIALS

Overview
RGH-MD-31
This flexible-dose study was conducted internationally, with approximately 60% of the subjects enrolled at US sites [27] . ; the press release reports that the LSMD obtained by MMRM at day 21 was -6.1 for cariprazine 3-6 mg/day and -5.9 points for cariprazine 6-12 mg/day, relative to patients receiving placebo Response is de ned as a decrease in the Young Mania Rating Scale of at least 50% from baseline, last observation carried forward (LOCF) Remission is de ned as a Young Mania Rating Scale total score no greater than 12 at LOCF endpoint washout off medications in an inpatient setting, 238 subjects were randomized (safety population included 236 subjects) to cariprazine or placebo.
Subjects randomized to cariprazine received 1.5 mg/day on day 1, and then titrated within the range of 3-12 mg/day based on response and tolerability as judged by the investigator.
Hospitalization was mandatory during screening and the first 2 weeks of double-blind treatment.
Discharge was possible on day 14 or after if the Clinical Global Impressions Severity (CGI-S) score was no greater than 3, the subject was otherwise not at significant risk for suicide or violent behavior, and was ready for discharge in the opinion of the investigator. Mean age of subjects ranged from 38 to 39 years across the two treatment arms; male gender ranged from 65% to 68%; white race ranged from 40% to 47%; and baseline YMRS total score ranged from 30 to 31.
In total, 36-38% of patients discontinued the In an analysis of single items from the YMRS, for each YMRS item cariprazine was statistically significantly superior to placebo. Mean changes in clinical laboratory values were small and similar between the groups except for slightly higher levels in liver enzymes for the cariprazine group.
Mean changes in blood pressure and pulse were higher in the cariprazine group relative to placebo.
The incidence of orthostatic hypotension or ECG changes was similar between cariprazine-and placebo-treated subjects. There was a higher incidence of extrapyramidal-related symptoms in the cariprazine group relative to placebo.
Treatment emergent adverse events with an incidence at least 5% for any of the cariprazine treatment arms and at least twice that for placebo were extrapyramidal disorder, akathisia, insomnia, vomiting, restlessness, sedation, vision blurred, and pain in extremity. Differences from placebo were generally small except for extrapyramidal disorder and akathisia where the numbers needed to harm (NNH) versus placebo were 7 and 8, respectively (see Table 4a [27]).
RGH-MD-32
This flexible-dose study was conducted internationally [28] . Differences from placebo were generally small except for akathisia and extrapyramidal disorder where the NNH versus placebo were 6 and 8, respectively (see Table 4b [28]). A total of 15 subjects receiving cariprazine discontinued because of an adverse event, with five because of akathisia.
RGH-MD-33
This study was conducted internationally [29] .
Inclusion criteria included a diagnosis of bipolar I disorder, manic or mixed type, with or without psychotic features. Subjects were 18-65 years of age. After up to 4-7 days of washout off medications in an inpatient setting, 497 subjects were randomized to cariprazine 3-6 mg/day, cariprazine 6-12 mg/day, or placebo.
In total, 23-30% of patients discontinued the trial prematurely. Statistically significant improvement was observed in both cariprazine dose groups versus placebo on the primary efficacy parameter. The most common adverse events (≥10% and twice the rate of placebo) observed in the study were akathisia (both cariprazine groups) and constipation (cariprazine 6-12 mg/day). Discontinuations due to adverse events occurred in 9%, 15%, and 5% of subjects in the cariprazine 3-6 mg/day, 6-12 mg/day, and placebo groups, respectively.
RGH-MD-52
This exploratory study was conducted in the Table 2 Table 5 [28, [34] [35] [36] ).
LONG-TERM CLINICAL TRIALS
RANDOMIZED CONTROLLED TRIALS IN PROGRESS
Number need to treat (NNT) values versus placebo for response and remission are available for two of the mania trials [27, 28] and can be found in Table 3 . The NNT for response of 5 or 7
is similar to that observed with data for lithium Provided that the akathisia is mild and timelimited this may not be a substantial obstacle for using cariprazine but in persons sensitive to akathisia this could be problematic. NNH values regarding somnolence for cariprazine versus placebo are similar to that for aripiprazole and appear more favorable than that observed for ziprasidone or asenapine (Table 5 ) [28, [34] [35] [36] .
Cariprazine is a potential alternative to aripiprazole [35, 37] . An important caveat is that none of the efficacy studies discussed have been published in peer-reviewed journals, and so the data presented must be considered preliminary and subject to revision.
Logical candidates for cariprazine treatment would be adults with bipolar manic/mixed episodes for whom sedation, metabolic, or cardiovascular risk is a concern, and for whom weight gain is to be minimized or avoided. AE adverse event, NNH number needed to harm (calculated as the reciprocal of the incidence of the AE on the drug of interest minus the incidence of the AE for placebo, and then rounded to the next highest whole number) from data contained in product labeling (prescribing information) available from the manufacturers [34] [35] [36] Patients who are sensitive to akathisia and extrapyramidal effects will need to be monitored for these adverse drug reactions. 
CONCLUSIONS
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